Tracking Eye Plaque Radiation Treatment for Eye Cancer: Finding the Right Dose
Prospective Registry of Ocular Melanoma Eye Plaque brachyTherapy Patients (PROMPT)
In Plain English
This study is collecting information from patients like you who are receiving (or have received) eye plaque brachytherapy—a targeted radiation treatment for uveal melanoma. Doctors place a small radioactive plaque directly on your eye tumor, kind of like a tiny radiation patch that stays in place for several days. The research team will track your treatment details and long-term results to answer an important question: Can we use lower doses of radiation that still kill the cancer effectively, but cause fewer side effects like vision problems or damage to the eye? You're not receiving a new experimental drug or treatment—this study simply collects data from standard care to help future patients get the best possible outcomes.
What This Trial Does
This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes. The goal of this study is to evaluate if lower doses of radiation can maintain high local control rates while minimizing the toxicities related to radiation therapy.
Who Can Join
Inclusion Criteria
- Patients 18 years of age or older with unilateral primary choroidal melanoma
- Patients with diagnosis of small or medium ocular melanomas amenable to plaque brachytherapy (as determined by treating ocular oncologist). Typically this would include tumors with apical height ≤10mm and basal diameter ≤16mm (small and medium tumors per COMS (Collaborative Ocular Melanoma Study)
- Patients with no clinical evidence of metastatic disease as confirmed by negative staging imaging (CT, MRI, and/or ultrasound)
- Patients with best-corrected visual acuity in the fellow eye of 20/200 or better
- Patients must be treated with IsoAid Eye Physics eye plaques
Exclusion Criteria
- Patients whose tumors are circumferential around the optic disc and cannot be adequately covered by the prescription dose are ineligible.
- Similarly, patients with extrascleral tumor extension detected during echography or clinical exam, diffuse, ring or multifocal tumors that cannot be encompassed in a single episcleral plaque or tumors judged to be predominantly ciliary body or iris melanoma will be considered ineligible
- Previous treatment for ocular melanoma in either eye or treatment of any condition secondary to the tumor are ineligible.
- Patients with a history of other primary or metastatic cancers are not eligible, except for non-melanotic skin cancers
- Patients with extraocular disease
Treatments
Data collection (OTHER)
Information about radiation therapy via eye plaque brachytherapy and follow up
Trial Sites (1)
Duke University Medical Center
Durham, North Carolina, United States